Nebenwirkungen · Fingolimod Accord
Fingolimod Accord 0.5 mg hard capsules · Abschnitt 4.8 · PDF-Seite 16
HOS-145267 · Präparat HOS-099320
Macular oedema incidence is increased in multiple sclerosis patients with a history of uveitis (17% with a history of uveitis vs. 0.6% without a history of uveitis). Fingolimod has not been studied in multiple sclerosis patients with diabetes mellitus, a disease which is associated with an increased risk for macular oedema (see section 4.4). In renal transplant clinical studies in which patients with diabetes mellitus were included, therapy with fingolimod 2.5 mg and 5 mg resulted in a 2-fold increase in the incidence of macular oedema.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T11:08:00Z · SHA-256 c38e617848fd32f3926aeca45feca8cfb462deb5bf6268c0fe28796f89fbcbff · Passage e98e971878c1d416349f367b4a0b2605f62d430f9e773fd5967d869355d5fc39 · Zeichen 6626–7168 im Abschnitt